PD1/PD-L1抑制剂治疗肿瘤

被引：18
|
作者：
赵宇飞
陈晓
李薇
机构：
[1] 吉林大学白求恩第一医院肿瘤中心
来源：
中国肿瘤生物治疗杂志 | 2017年 / 24卷 / 08期
关键词：
程序死亡分子; 程序死亡分子配体1; 安全性; 疗效; 恶性肿瘤;
D O I：
暂无
中图分类号：
R730.5 [肿瘤治疗学];
学科分类号：
摘要：
近年来,程序死亡分子(programmed death-1,PD1)/PD1配体(PD1 ligand,PD-L1)抑制剂在黑色素瘤的治疗中取得了突破性进展,并迅速应用到其他类型肿瘤,其中包括肺癌、乳腺癌、肝癌、胰腺癌、消化道肿瘤、妇科肿瘤、泌尿系统肿瘤以及骨髓瘤和淋巴瘤等多种恶性肿瘤,许多临床试验证明了抗PD1/PD-L1治疗可显著改善癌症患者生存期,并且治疗相关不良反应耐受性尚可。目前关于其抗肿瘤活性及安全性的研究仍在继续,并进一步探索其诊断、疗效评估的理想生物标记物,以及用于长期监测的方法,期待这些问题的解决,使抗PD1/PD-L1治疗更加系统、完善,为更多的癌症患者带来生存获益。
引用
收藏
页码：904 / 911
页数：8
相关论文
共 13 条
  • [1] Anti program death-1/anti program death-ligand 1 in digestive cancers[J]. Eléonore de Guillebon,Pauline Roussille,Eric Frouin,David Tougeron.World Journal of Gastrointestinal Oncology. 2015(08)
  • [2] Efficacy of immunotherapy for metastatic mucosal melanoma
    Shreders, Amanda
    Joseph, Richard W.
    [J]. IMMUNOTHERAPY, 2016, 8 (08) : 843 - 845
  • [3] Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8+ T cells
    Leng, Changsen
    Li, Yin
    Qin, Jianjun
    Ma, Jun
    Liu, Xianben
    Cui, Yingying
    Sun, Haibo
    Wang, Zongfei
    Huai, Xionghuai
    Yui, Yongkui
    Li, Haomiao
    Zhang, Jun
    Zheng, Yan
    Wang, Wei
    Zhui, Jijnwei
    Wang, Qiuming
    [J]. ONCOLOGY REPORTS, 2016, 35 (02) : 699 - 708
  • [4] Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
    Mehnert, Janice M.
    Panda, Anshuman
    Zhong, Hua
    Hirshfield, Kim
    Damare, Sherri
    Lane, Katherine
    Sokol, Levi
    Stein, Mark N.
    Rodriguez-Rodriquez, Lorna
    Kaufman, Howard L.
    Ali, Siraj
    Ross, Jeffrey S.
    Pavlick, Dean C.
    Bhanot, Gyan
    White, Eileen P.
    DiPaola, Robert S.
    Lovell, Ann
    Cheng, Jonathan
    Ganesan, Shridar
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (06): : 2334 - 2340
  • [5] Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study[J] . Scott Antonia,Sarah B Goldberg,Ani Balmanoukian,Jamie E Chaft,Rachel E Sanborn,Ashok Gupta,Rajesh Narwal,Keith Steele,Yu Gu,Joyson J Karakunnel,Naiyer A Rizvi.The Lancet Oncology . 2016 (3)
  • [6] The Basis of OncoImmunology[J] . A. Karolina Palucka,Lisa M. Coussens.Cell . 2015
  • [7] Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
    Hamanishi, Junzo
    Mandai, Masaki
    Ikeda, Takafumi
    Minami, Manabu
    Kawaguchi, Atsushi
    Murayama, Toshinori
    Kanai, Masashi
    Mori, Yukiko
    Matsumoto, Shigemi
    Chikuma, Shunsuke
    Matsumura, Noriomi
    Abiko, Kaoru
    Baba, Tsukasa
    Yamaguchi, Ken
    Ueda, Akihiko
    Hosoe, Yuko
    Morita, Satoshi
    Yokode, Masayuki
    Shimizu, Akira
    Honjo, Tasuku
    Konishi, Ikuo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4015 - +
  • [8] Concurrent Immunotherapy and Stereotactic Radiosurgery for Brain Metastases Is Associated With a Decreased Incidence of New Intracranial Metastases
    Chen, L.
    Douglass, J.
    Walker, A. J.
    Marciscano, A. E.
    Lim, M.
    Kleinberg, L. R.
    Forde, P.
    McNutt, T. R.
    Redmond, K. J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E102 - E102
  • [9] The prognostic significance of PD-L1 in bladder cancer
    Huang, Yide
    Zhang, Shu-Dong
    McCrudden, Cian
    Chan, Kwok-Wah
    Lin, Yao
    Kwok, Hang-Fai
    [J]. ONCOLOGY REPORTS, 2015, 33 (06) : 3075 - 3084
  • [10] Tumor Cell Expression of Programmed Cell Death-1 Ligand 1 Is a Prognostic Factor for Malignant Melanoma
    Hino, Ryosuke
    Kabashima, Kenji
    Kato, Yu
    Yagi, Hiroaki
    Nakamura, Motonobu
    Honjo, Tasuku
    Okazaki, Taku
    Tokura, Yoshiki
    [J]. CANCER, 2010, 116 (07) : 1757 - 1766
12